Suggested remit: To appraise the clinical and cost effectiveness of voclosporin with immunosuppressive therapies within its marketing authorisation for treating lupus nephritis.
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3962

Provisional Schedule

Committee meeting: 1 02 November 2022
Expected publication 25 January 2023

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Otsuka Pharmaceuticals (voclosporin)
Others Department of Health and Social Care
  NHS Bath and North East Somerset CCG
  NHS England
  NHS Fylde & Wyre CCG
  Welsh Government
Patient carer groups AOFAC Foundation
  Arthritis Action
  Arthritis & Musculoskeletal Alliance
  British Sjögren’s Syndrome Association
  Genetic Alliance UK
  Gene People
  Kidney Care UK
  Lupus Trust
  Lupus UK
  National Kidney Federation
  National Rheumatoid Arthritis Society
  Polycystic Kidney Disease Charity
  Raynaud’s & Scleroderma Association
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Renal Industrie
  Asociation of Renal Technologists
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Isles Lupus Assessment Group
  British Renal Society
  British Society for Allergy and Clinical Immunology
  British Society for Haematology
  British Society for Rheumatology
  British Society of Haemostasis and Thrombosis
  Clinical Leaders of Thrombosis
  Primary Care Rheumatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Society of Medicine
  Society for DGH Nephrologists
  Society for Vascular Technology
  Society of Vascular Nurses
  UK Clinical Pharmacy Association
  UK Kidney Association
  UK Renal Pharmacy Group
  United Kingdom Primary Immunodeficiency Network
  Urology Foundation
  Vascular Society of Great Britain and Ireland
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (mycophenolate mofetil, prednisolone)
  Aspen (azathioprine)
  ADVANZ Pharma (prednisolone)
  Astellas Pharma (tacrolimus)
  Baxter Healthcare (cyclophosphamide)
  Chiesi (tacrolimus)
  Dexcel Pharma (ciclosporin)
  Ennogen Pharma (azathioprine)
  Mylan (azathioprine, ciclosporin)
  Napp Pharmaceuticals (rituximab)
  Nova Laboratories (azathioprine)
  Novartis Pharmaceuticals (ciclosporin, mycophenolic acid as mycophenolate sodium)
  Pfizer (methylprednisolone, rituximab)
  Phoenix Labs (prednisolone)
  Relonchem (azathioprine)
  Roche Products (mycophenolate mofetil, rituximab)
  Sandoz (cyclophosphamide, mycophenolic acid as mycophenolate sodium, rituximab, tacrolimus)
  Strides Pharma UK (azathioprine)
  Teva Pharma (mycophenolate mofetil)
  Tillomed Laboratories (azathioprine, mycophenolate mofetil)
  Wockhardt (prednisolone)
  Zentiva (prednisolone)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  NHS England Specialised Rheumatology Clinical Reference Group
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Antithrombotic Trialists’ Collaboration
  British Epidermo-Epidemiology Society
  Cochrane Kidney and Transplant Group
  Cochrane UK
  Cochrane Vascular Disease
  Genomics England
  Kidney Research UK
  MRC Clinical Trials Unit
  National Institute for Health Research
  Thrombosis Research Institute


Key events during the development of the guidance:

Date Update
04 March 2022 In progress. Invitation to participate
04 March 2022 Invitation to participate
09 November 2021 - 07 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual